Business
Next Shares Jump 6% as UK Retailer Raises Profit Forecast for the Third Time This Year on Strong Sales
LONDON — Shares of Next PLC surged Wednesday after the British fashion and homewares retailer raised its full-year profit forecast for the third time this year, delivering a trading update that reinforced its status as a bellwether for the strength of UK consumer spending even amid a broader cautious retail environment.
Next shares climbed as much as 7% in early trading, touching a fresh all-time high of 15,900 pence, before settling to a gain of 6.21%, or 920 pence, to close at 15,730 pence. The advance gave the retailer a market capitalization of £17.72 billion and extended a rally that has now pushed the stock up close to 19% so far this year.
A Third Upgrade in a Single Year
Next said full-price sales rose 9.2% in the 13 weeks to Aug. 1, comfortably outpacing the company’s own previous forecast of just 4% growth for the quarter, a target it had set after full-price sales growth of 6.2% in the first quarter reflected a tougher comparison with the prior year. Instead, sales came in £70 million ahead of the retailer’s expectations, split between a £19 million beat in the UK and a £51 million beat overseas.
On the back of that outperformance, Next raised its full-year pretax profit guidance by £25 million to £1.243 billion for the year ending January 2027, representing year-on-year growth of 7.3%. The company said £15 million of the increase stemmed from the additional sales, while the remaining £10 million reflected better-than-expected returns on its equity investments. Full-year earnings per share guidance was lifted to 812.9 pence, up 9.2% from the prior year.
The upgrade marks the third time Next has raised its profit outlook so far this year, following earlier increases from an initial forecast of £1.158 billion to £1.218 billion ahead of Wednesday’s announcement. According to one broker cited in coverage of the results, the pattern is a familiar one for the retailer, which has issued 19 profit upgrades since the start of its 2024 financial year, a track record that has made repeated guidance increases almost an expected feature of Next’s reporting calendar rather than a surprise.
Warm Weather and Middle East Demand Drive the Beat
Next attributed the stronger-than-expected quarter in part to weather conditions that matched the exceptionally warm summer seen the previous year, a factor the company said it had not anticipated when it issued its more cautious original guidance. The retailer also pointed to a release of pent-up consumer demand in the Middle East and Northern Europe, regions that had posted weaker sales performance in the first quarter before rebounding strongly in the second.
International online sales were the standout performer in the update, surging 36.9% during the second quarter and pushing first-half international online growth to 23.9%. By contrast, total UK sales rose a more modest 2.8% during the quarter, as a 0.3% decline in physical store sales was offset by 5% growth in UK online sales. Across the first half of the year as a whole, total full-price sales rose 7.7%.
Guidance for the Remainder of the Year
Despite the strong second-quarter beat, Next held its forecast for full-price sales growth in the second half of the year unchanged at 5%, a decision the company framed as appropriately cautious given the scale of the comparatives it will be lapping. The retailer specifically flagged that international sales growth is expected to moderate to around 14% in the second half, down from the elevated pace seen in recent quarters, as the comparison period begins to include the benefit of logistics upgrades made to its European distribution network the previous year.
Taken together, the updated guidance implies full-year full-price sales of £6 billion, up from a previous forecast of £5.9 billion, and total group sales of £7.5 billion, up from £7.3 billion previously. The updated forecast also assumes £524 million in share buybacks for the year, £14 million above the company’s prior guidance, underscoring Next’s continued emphasis on returning capital to shareholders alongside its operational growth.
A Bellwether for UK Retail
Next is widely regarded by analysts and investors as one of the clearest bellwethers for the health of British consumer spending, given its scale, with more than 800 stores across the UK and Ireland alongside a substantial international online operation. The company’s consistent pattern of upgrading guidance throughout 2026 has stood in contrast to a broader retail sector narrative that has often emphasized caution around consumer spending power amid persistent cost-of-living pressures across the UK.
Next’s international third-party brand business, which sells other companies’ products through its online platform alongside its own Wholly Owned Brands, has continued to expand as part of the company’s broader growth strategy, with international third-party brand sales having grown 22% year over year in the company’s most recent full fiscal year. The retailer has also continued to flag Middle East regional instability as a source of ongoing logistical and cost challenges, having previously estimated tens of millions of dollars in additional costs tied to fuel and air freight disruptions linked to the conflict in the region.
Next’s interim results are due to be published on Sept. 17, 2026, an event that investors and analysts are likely to watch closely for further detail on how the retailer’s momentum has carried into the back half of its financial year, along with any additional commentary on cost pressures tied to ongoing instability in the Middle East. With Wednesday’s upgrade marking the company’s third of the year and shares now trading at record levels, market attention is increasingly focused on whether Next’s pattern of beating its own conservative guidance can be sustained into the more challenging comparative period the retailer itself has flagged for the months ahead.
Business
(VIDEO) Kansas Mother of Four Recovering After Suspected Spider Bite Causes Severe Liver Complications
WICHITA, Kan. — A Kansas mother of four is continuing her recovery at home after a suspected spider bite during a Memorial Day weekend campfire triggered a cascade of medical complications that left her fighting for her life, including surgery, dangerous infections and a diagnosis of end-stage liver failure that doctors warned could be fatal.
Britagne Miller, of Goddard, a small city roughly 14 miles west of Wichita, said she was sitting around a campfire with her husband, Jake, and their four children at Cheney Lake on May 28 when several spiders crawled onto her and bit her multiple times, according to local outlets KAKE and FOX Kansas. At the time, none of the bites seemed cause for immediate concern.
A Bite That Kept Getting Worse
Four days later, the situation changed. The area surrounding one bite on Miller’s calf began to swell and grow increasingly painful, prompting her to seek medical care. Describing the sensation to KAKE, Miller said the bite kept swelling and swelling, comparing the feeling to a hot metal fire poker shooting down her leg into her foot, as though she were being stabbed.
Miller was admitted to Wesley Hospital in Wichita on June 4, where doctors performed surgery to address the wound. According to a GoFundMe campaign created by her husband and reporting from KAKE, surgeons removed nearly 300 milliliters of blood clots from the affected area and inserted a drain to help the wound heal.
Complications Multiply
Miller’s treatment quickly grew more complicated. Following the surgery, the wound became infected with both a staph infection and a separate gram-negative bacterial infection, according to KAKE. Her situation was further complicated by preexisting health conditions, including blood-clotting disorders first diagnosed during a previous pregnancy, along with an already compromised liver and allergies to certain medications that limited her treatment options.
As her condition worsened, doctors determined that Miller was suffering from end-stage liver failure and warned her family that her condition could ultimately prove fatal, according to KAKE. Doctors reportedly gave her a prognosis ranging from just days to as little as a month to live. Miller was placed in both medical and cardiac intensive care during the most critical stretch of her hospitalization.
Despite the grim outlook, Miller made the decision to continue pursuing treatment rather than enter hospice care. Recalling the moment she absorbed the severity of her diagnosis, Miller told KAKE that her first thought was that she was done, before her focus immediately shifted to her husband and children. She has said she remembers little from her time in intensive care, a period she described as largely a blur given the severity of her condition.
A Long Road to Recovery
Miller spent roughly 10 days in intensive care before being discharged from the hospital on July 11, bringing her total hospitalization to approximately 44 days. She is now continuing her recovery at home, though her medical journey is far from over. According to her family, Miller now requires ongoing home health care, physical therapy to help her relearn how to walk on her injured leg, and regular visits with specialists in the months ahead.
Perhaps most significantly, Miller still needs a liver transplant, but she is not yet eligible to be placed on a transplant waiting list. Doctors have said her blood clotting levels and other lab values must first stabilize before that process can move forward, leaving her family in a continued state of uncertainty even as she has moved past the most immediate danger.
An Unconfirmed but Suspected Culprit
Despite the severity of Miller’s reaction, doctors have not definitively confirmed which species of spider was responsible for the bite. Based on the appearance of the wound and the region in which the incident occurred, medical staff believe it is consistent with a bite from a brown recluse spider, according to Miller and reporting from KAKE.
Dr. Raymond Cloyd, a horticultural entomologist at Kansas State University, told KAKE that the brown recluse and the black widow are the two venomous spider species most commonly found in Kansas. According to the Cleveland Clinic, brown recluse spiders are typically not aggressive toward humans, and their bite is usually painless at the moment it occurs. In most cases, a bite produces only a red, itchy reaction that resolves without serious complications. However, if left untreated, a brown recluse bite can progress to bruising, blistering, an open sore and lasting scarring. In rare and severe cases, symptoms can include rash, fever, dizziness, vomiting and chills, alongside more serious systemic effects, particularly in individuals with preexisting health vulnerabilities such as compromised organ function or clotting disorders, conditions that closely mirror those Miller was already managing before the bite occurred.
Practical Precautions
For those looking to avoid similar encounters, Cloyd advised sealing cracks and gaps around homes and outdoor structures, and exercising caution when handling boxes, shoes and other items that have gone undisturbed for extended periods, common hiding spots for spiders such as the brown recluse.
A Family Leaning on Community Support
As Miller continues her recovery, her family has turned to a GoFundMe campaign to help offset the costs associated with her extended hospitalization and ongoing medical needs. In an update shared through the campaign, the family expressed hope for better days ahead, writing that although there remains a long road ahead, they are holding on to hope that this season will eventually be behind them and that Miller will be able to return fully to the roles she cherishes most, being a mother now, and someday a grandmother.
Fox News Digital reported it was unable to immediately reach the Miller family for additional comment. As Miller works toward eligibility for a liver transplant, her case has drawn renewed attention to the potential severity of spider bites, particularly for individuals with underlying health conditions that can complicate what might otherwise be a minor, self-resolving injury for most healthy people.
Business
CVS Stock Down On Early Warnings About 2027
CVS Health saw its shares dip about 6% even though it handily beat Wall Street’s expectations for the most recent quarter and raised its guidance for 2026 earnings. The issue was the company’s unusually early commentary about 2027.
The healthcare giant warned that membership in its Caremark pharmacy-benefits manager will decline next year, as it rewrites contracts to reflect a new pricing model and as some of its insurer clients pull back from certain markets. The warning comes amid broader investor concern about the evolving financial model of PBMs.
The company also flagged pressures related to the 340B drug-discount program. CVS offered a more upbeat view of continued improvements at Aetna, its insurance arm.
Business
Prioritise new jobs over green targets to win public contracts, firms told
Andy Burnham will tell firms bidding for public contracts to prove they are creating jobs rather than meeting green and social targets in a bid to get more people into work.
The prime minister will overhaul the £90bn public procurement system so bidders have to show they are supporting young people into work and addressing local skills shortages.
It comes as the government seeks to tackle the youth unemployment crisis, with Burnham saying he wants to create “growth in every postcode”.
But green groups criticised the plans, arguing supporting young people into work should not come at the expense of the environment.
Companies bidding for government contracts are judged on a range of measures, including value for money and the extent to which they bring benefits to the local community.
Under the changes, the weighting given to the benefits brought by companies will be doubled, from 10% to 20% for contracts worth £5m or more, the Cabinet Office said.
Previously, this accounted for how companies created social value through measures such as equality and diversity, net zero and the post-Covid recovery.
The new 20% measure will instead be based on job creation. Bidders will be given extra credit for creating local jobs paying above the minimum wage, plugging local skills gaps by offering training and particularly by offering 45-day work experience placements for young people.
Office for National Statistics (ONS) figures show more than a million people aged 16 to 24 are currently not in education, employment or training (Neet).
Burnham used a similar initiative to oversee a rise in the latter during his time as mayor of Greater Manchester.
First Secretary of State Louise Haigh — who is effectively Burnham’s deputy prime minister — said the procurement process in its current form was a “tick-box exercise”.
“Every pound of taxpayer money should be spent in a way that benefits local communities — creating good jobs and giving young people the skills they need for the future,” she said.
The new model will apply to both British and international firms bidding for public contracts.
Haigh said: “These new rules will ensure the £90 billion that is spent each year through government contracts supports British jobs, skills and people in every postcode.”
Cabinet Office Minister Mark Ferguson said that businesses who secure government contracts “have a responsibility to give back”.
“Businesses that benefit from the billions of taxpayer pounds spent by government, will have to create more local jobs and opportunities for young people in their area,” he said.
But Greenpeace UK’s head of politics Ami McCarthy said protecting the environment and helping young people into work are “mutually beneficial and one shouldn’t come at a cost to the other”.
“Companies should be held to account with environmental targets to help achieve a better future without leaving young workers behind,” she added.
Business
ADP report July 2026: Private sector adds 44,000 jobs
Citi Wealth head of economics Conrad Dequadros and FOX Business co-host Taylor Riggs analyze the S&P 500 hitting all-time highs under President Donald Trump’s economic policies on ‘Kudlow.’
Companies in the private sector added 44,000 jobs in July, payroll processing firm ADP said in its latest report on Wednesday.
The figure is below economists’ estimates of a gain of 70,000 jobs and down from the prior month’s revised 95,000 payrolls figure.
“Job-changers are highly sensitive to real-time economic conditions, and their rapid pay growth implies supply constraints in parts of the labor market,” said Nela Richardson, ADP’s chief economist. “Typical hiring patterns, meanwhile, are changing as employers react to shifting macro-economic conditions.”
THE COLLEGES THAT GIVE GRADUATES THE STRONGEST CAREER EDGE, ACCORDING TO LINKEDIN

Companies in the private sector added 44,000 jobs in July. (Joe Raedle/Getty Images)
Which industries are hiring the most workers, according to the ADP report?
Education and health services added 36,000 positions, leading job creation in July. Financial activities added 10,000, professional and business services gained 9,000, and other services added 6,000.

Education and health services led hiring in the month of July, according to ADP. (iStock)
US WORKERS INCREASINGLY TRAPPED IN THE ‘GREAT DETACHMENT’ AS HIRING SLOWS, REPORT SHOWS
Information added 5,000 jobs, while manufacturing construction added 2,000 and 1,000 positions, respectively.
On the negative side, leisure and hospitality lost 11,000 jobs, trade, transportation and utilities lost 8,000, and natural resources and mining lost 6,000.
Large businesses – those with 500 or more employees – gained 13,000 jobs in July. Businesses with 50 to 499 employees gained 8,000 workers. Establishments with fewer than 50 employees gained 23,000 jobs.
SOUTHERN CITIES DOMINATE RANKINGS OF BEST JOB MARKETS FOR NEW COLLEGE GRADUATES

Small businesses hired 67,000 workers in May, according to the latest ADP data. (Getty Images)
People staying in their roles saw their pay climb 4.4% from the prior year, while pay gains for those changing their jobs accelerated to 7% – the largest year-over-year increase since August 2025.
Business
Sterlite Tech, HFCL gain 5% each on reports of US ban on Chinese data centre devices
According to a Reuters report, the Trump administration is drafting a ban on US imports of new models of Chinese data centre components, citing four people familiar with the matter. The move is aimed at protecting the infrastructure supporting the rapid growth of artificial intelligence.
Also Read |PNB Housing Finance shares rally 5% after Q1 profit rises 4% YoY, loan assets jump 15%
The report further said that the Federal Communications Commission (FCC), which oversees the US telecom industry, is working on a measure to bar imports of new Chinese optical transceivers. These components enable data to travel over fibre-optic cables at the speed of light within data centres.
The move, which has not been previously reported, aims to prevent Chinese firms from stealing data, installing malware or disrupting services at US data centres that house the chips used to train and run AI models.
Reuters reported that the FCC could still modify or shelve the proposed restriction, with sources speaking on condition of anonymity due to the sensitive nature of the matter. However, the move marks another effort by the Trump administration to limit Chinese technological influence in critical US industries before such products become embedded in supply chains.
“Transceivers definitely pose a risk. As the data centre buildout scales up, you want to make sure the data centre supply chain is secure from the get-go,” said Divyansh Kaushik, an AI policy expert at Washington, DC-based advisory firm Beacon Global Strategies.In an exchange filing on Tuesday, HFCL said its board has approved a further expansion of its optical fibre and optical fibre cable manufacturing capacities, with a total capital outlay of around Rs 400 crore. The expansion will be funded through an appropriate mix of internal accruals and debt, as required.
HFCL said the decision was supported by its strong order book for optical fibre cable (OFC) and optical connectivity products, a robust pipeline of additional business opportunities, and a favourable long-term global demand outlook.
The company added that demand is being driven by rising investments in artificial intelligence (AI) infrastructure, hyperscale data centres, cloud computing, high-performance computing, 5G deployments, FTTH and broadband expansion, enterprise fibreisation, rural connectivity initiatives and telecom network modernisation programmes.
Also Read | MapMyIndia shares drop 8% despite strong Q1 earnings; PAT jumps 8% YoY
This proposed expansion is in addition to the company’s ongoing expansion programme. The board has now approved an additional capacity expansion of 4.60 million fkm per annum in optical fibre (OF) and 14.0 million fkm per annum in optical fibre cable (OFC) capacities. Upon completion of these expansion programmes, HFCL’s total OF manufacturing capacity will increase to 38.50 million fkm per annum, while OFC manufacturing capacity will rise to 56.36 million fkm per annum.
The proposed expansion is expected to be completed by July 2028. It is aimed at helping the company cater to rising demand for OFC and optical connectivity products across domestic and international markets, while addressing requirements from existing customer commitments, a healthy order book and an expanding business pipeline.
The Reuters report also highlighted that such a ban could increase costs for US cloud firms such as Amazon Web Services, as they may have to shift to alternative suppliers, including US-based Coherent and Lumentum.
Earlier, the FCC had imposed similar curbs on Chinese drones, routers, robots and inverters.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Business
Saudi-led group completes $55bn purchase of gaming giant EA
The sale of gaming giant Electronic Arts (EA) for $55bn (£41bn) to a group of buyers including Saudi Arabia’s Public Investment Fund (PIF) has been finalised.
The American company is known for making and publishing best-selling games such as EA FC, formerly known as Fifa, The Sims and Mass Effect.
The investors, who include Affinity Partners – led by President Donald Trump’s son-in-law, Jared Kushner – are taking EA private, meaning all of its public shares will be purchased and it will no longer be traded on a stock exchange.
It is thought to be the largest leveraged buyout in history, meaning a significant part of it is paid for with borrowed money, which the company will have to pay back.
This is because as well as the $36bn it has already put into the deal, PIF needs to borrow $20bn from investment bankers JPMorgan to close it, with the business taking on the debt.
How paying back this debt will affect EA as a business has been the source of much speculation from journalists and analysts.
Bloomberg’s Jason Schreier surmised it could lead to “mass layoffs, more aggressive monetization, and other big cost-cutting measures, external“, for one of the industry’s biggest companies.
Christopher Dring, editor-in-chief and co-founder of the Game Business, said the nature of the buyout, external was also likely to mean “a very hands-on approach from the investment group”.
“Private equity firms are typically aggressive in their management of companies,” he said.
Shams Jorjani, the chief executive of Arrowhead Game Studios – an independent studio which worked with publishers Sony to make the record-breaking Helldivers 2 – told the BBC that EA has traditionally been seen as having a wide portfolio of games, from blockbusters to smaller indie titles.
“This deal is consolidation, no question – and I wonder whether new ownership optimises for the safe bet – more sequels, more mega-franchises – over that breadth,” he said.
“I’m hopeful this leads to more of that range, not less, but if it turns EA into a sequel-and-mega-franchise machine, that’s a real waste of one of the best catalogues in the industry.”
Business
Apple's Selloff Is Overdone
Apple's Selloff Is Overdone
Business
The 2 Most Misunderstood 10%+ Yielding Income Investments In The Market Today
The 2 Most Misunderstood 10%+ Yielding Income Investments In The Market Today
Business
Beef remains a problem for Tyson Foods

Business unit volume fell 16% during the third quarter.
Business
Eli Lilly (LLY) earnings Q2 2026
The Eli Lilly logo appears on the company’s office in San Diego, California, Nov. 21, 2025.
Mike Blake | Reuters
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro surged again.
The pharmaceutical giant now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion to $85 billion.
Lilly projects its full-year adjusted profit to be between $35.50 and $36.50 per share, which compares with a previous outlook of $35.50 to $37 per share. The company said it raised the underlying profit guidance by $2.78 per share at the midpoint, but noted that it is offset by $3.03 per share in charges tied to deals in the quarter.
Shares of Lilly rose more than 5% in premarket trading Wednesday.
Fueled by a massive financial windfall from its obesity and diabetes drugs, Lilly is executing a historic M&A spending spree. The company most recently struck a deal to buy a psychedelics drugmaker in July, and also announced plans to buy three vaccine makers in May.
Resilient demand for Zepbound and Mounjaro has helped fuel several strong quarters for Lilly despite lower prices for the medications in the U.S.
Mounjaro’s worldwide revenue rose 91% to $9.94 billion for the quarter, including U.S. sales of $4.8 billion. That surpassed the $8.99 billion in worldwide sales and $4.44 billion in U.S. revenue that analysts were expecting for the quarter, according to StreetAccount.
Mounjaro notably saw strength internationally, with sales outside the U.S. jumping 172%.
Zepbound, which entered the market roughly three years ago, posted $4.93 billion in U.S. revenue for the second quarter. That’s up 44% from the year-earlier period, as demand for the drug also rose while realized prices dropped, in part due to previously announced cash-pay discounts. Analysts were expecting $4.69 billion in U.S. sales for Zepbound, according to StreetAccount.
Lilly’s newly launched obesity pill, Foundayo, which won U.S. approval in April, took in $98 million in sales for the second quarter. Analyst estimates compiled by FactSet as of Wednesday forecasted nearly $103 million in sales.
It marks the first earnings report that includes revenue from the GLP-1 pill, which is competing head-to-head with a rival oral drug from Novo Nordisk that rolled out a few months ahead.
Here’s what Eli Lilly reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:
- Earnings per share: $8.38 adjusted vs. $6.01 expected
- Revenue: $22.97 billion vs. $20.73 billion expected
Revenue in the U.S. climbed 33% to $14.4 billion. Lilly said it saw a 37% increase in volume — or the number of prescriptions or units sold — for its products, primarily for Mounjaro and Zepbound. That was partially offset by lower realized prices of those same medications.
Notably, revenue outside the U.S. jumped 80% to $8.6 billion, propelled by a 113% surge in volume and partly offset by a 36% drop in realized prices. Lower prices largely came from Mounjaro’s addition to China’s state-run health insurance coverage for Type 2 diabetes.
The pharmaceutical giant booked net income of $7.10 billion, or $7.94 per share, for the second quarter, which includes the $3.03 per share deal charges. That compares with net income of $5.66 billion, or $6.29 per share, a year earlier.
Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted earnings of $8.38 per share for the second quarter.
Eli Lilly CEO Dave Ricks said in an interview in late April that he expects lower prices to accelerate prescription volumes in the U.S. He estimated that global GLP-1 use will rise from approximately 20 million patients at the end of last year to 30 million at the end of 2026.
Both Lilly and Novo are expected to benefit from Medicare’s new coverage of obesity drugs, which launched in early July, in the back half of the year.
-
Business7 days agoWhy Trees Belong on the Risk Register
-
Fashion5 days agoWeekend Open Thread: Wit & Wisdom
-
Politics5 days agoMeta enters AI-training agreement with far-right ‘propaganda rag’ Newsmax
-
Politics7 days agoReform UK betrays West Mids residents by running from party pledges
-
Politics3 days agoZack Polanski: an incitement to murder Nigel Farage?
-
Crypto World4 days agoMicroStrategy Post-Earnings CLARITY Act Push Could Add New Catalyst for Its Stock
-
Crypto World4 days agoXRP Ledger v3.3.0 brings five institutional features
-
News Videos6 days agoBitcoin Enters the 3rd Stage of the Bear Market
-
Politics6 days agoLuke Littler’s dominance sparks GOAT debate
-
Sports6 days agoSeema Kaliramna Wins Discus Throw Bronze, Takes India’s CWG Medals Tally To 17
-
Crypto World5 days agoNew York sues Kalshi over prediction market gambling
-
Crypto World3 days agoCrypto PAC spending tops $2M in Michigan House race
-
Business5 days agoTrump Announces Hamas Disarmament Agreement as Iran Strikes Kuwait Air Base and US Attacks Pause Overnight
-
Tech3 days agoESET tracks rise in malicious AI skills and adaptable malware
-
Business3 days agoDTCR: Deleveraging And A Hedge Fund Collapse Point To A Possible AI Bottom
-
Crypto World5 days ago3 Fed Officials Just Explained Their Rate Hike Vote: Is Inflation Winning?
-
Tech5 days agoGemini Spark can now use Chrome logins and saved passwords to run errands on your behalf
-
Tech5 days agoBuilding A Reproduction PlayStation Motherboard
-
NewsBeat6 days agoFour people die trying to cross Channel in small boats
-
Sports4 days agoFrance Cricket implodes: letters hidden in a drawer and a board at war

You must be logged in to post a comment Login